Identify, Develop and Expand
Our Strategy
Cumberland Pharmaceuticals is a unique company that is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs. These are the three key elements of our growth strategy.
Our strategy involves identifying earlier stage product candidates that have the potential to improve patient care.
Our majority-owned subsidiary, Cumberland Emerging Technologies (CET) is for just that purpose. We supplement our late-stage development initiatives with CET’s early-stage drug development activities. CET represents a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, the state of Tennessee supported LaunchTN, and WinHealth Pharma. The mission of CET is to identify promising new biomedical products and advance them towards the marketplace. At CET we have established a series of collaboration agreements with a
select group of academic research institutions located across the mid
south region of the U.S. We work with our university partners to identify
and establish arrangements for each new product candidate. We then
team with the university scientific team to support product development
and also identify opportunities to secure grant funding.
Our strategy involves developing differentiated products. Our clinical team is developing a pipeline of new product candidates to address poorly met medical needs.
Our efforts will allow Cumberland to selectively build a portfolio of differentiated, safe and effective products for underserved patient populations.
Cumberland is continually evaluating new opportunities to support patients who can benefit from our product candidates by exploring potential new indications and designing new product presentations.
The Company focuses on a concentrated prescriber base. Our development efforts are focused on expanding our reach within the medical community and keeping health care providers informed of how our product candidates are able to improve the quality of care for their patients. The combination of our ongoing development activities and partnership efforts will drive the success of our products.